Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix (NASDAQ:CMRX) has announced the granting of inducement awards to six new employees on January 17, 2025. The awards consist of non-statutory stock options to purchase up to 355,000 shares of Chimerix's common stock. The stock options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following three years.
The exercise price is set at Chimerix's closing trading price on the grant date. While subject to the terms of Chimerix's 2024 Equity Incentive Plan, these grants were made outside of it. The company, a biopharmaceutical firm, is currently developing dordaviprone (ONC201) for H3 K27M-mutant glioma and conducting Phase 1 dose escalation studies of ONC206.
Chimerix (NASDAQ:CMRX) ha annunciato la concessione di premi incentivanti a sei nuovi dipendenti il 17 gennaio 2025. I premi consistono in opzioni su azioni non statutarie per l'acquisto di fino a 355.000 azioni ordinarie di Chimerix. Le opzioni su azioni hanno una durata di 10 anni e si matureranno nel corso di quattro anni, con il 25% che si matura dopo un anno e il restante 75% che si matura mensilmente nei tre anni successivi.
Il prezzo di esercizio è fissato al prezzo di chiusura delle azioni di Chimerix alla data di concessione. Sebbene siano soggetti ai termini del Piano di Incentivazione Azionaria 2024 di Chimerix, questi premi sono stati concessi al di fuori di esso. L'azienda, una società biofarmaceutica, sta attualmente sviluppando dordaviprone (ONC201) per il glioma mutante H3 K27M e sta conducendo studi di escalation della dose di Fase 1 per ONC206.
Chimerix (NASDAQ:CMRX) ha anunciado la concesión de premios de incentivos a seis nuevos empleados el 17 de enero de 2025. Los premios consisten en opciones sobre acciones no estatutarias para la compra de hasta 355,000 acciones ordinarias de Chimerix. Las opciones sobre acciones tienen un plazo de 10 años y se consolidarán durante cuatro años, con un 25% que se consolidará después de un año y el restante 75% que se consolidará mensualmente durante los siguientes tres años.
El precio de ejercicio se establece en el precio de cierre de las acciones de Chimerix en la fecha de concesión. Aunque están sujetos a los términos del Plan de Incentivos de Capital 2024 de Chimerix, estos premios se otorgaron fuera de él. La empresa, una firma biofarmacéutica, está desarrollando actualmente dordaviprone (ONC201) para el glioma mutante H3 K27M y realizando estudios de escalamiento de dosis de Fase 1 para ONC206.
Chimerix (NASDAQ:CMRX)는 2025년 1월 17일에 6명의 신규 직원에게 유인 보상을 부여한다고 발표했습니다. 보상은 Chimerix의 보통주 355,000주를 구매할 수 있는 비법정 주식 옵션으로 구성됩니다. 주식 옵션의 유효 기간은 10년이며, 4년 동안 분할해야 하며, 1년 후에 25%가 만료되고 나머지 75%는 다음 3년 동안 매월 만료됩니다.
행사가는 부여일에 Chimerix의 종가로 설정됩니다. Chimerix의 2024년 자본 인센티브 계획의 조건에 따라 진행되지만, 이 보상은 그 외부에서 이루어졌습니다. 이 회사는 생명공학 제약 업체로 dordaviprone (ONC201)을 H3 K27M 변이 교모세포종을 위해 개발 중이며 ONC206의 1단계 용량 상승 연구를 실시하고 있습니다.
Chimerix (NASDAQ:CMRX) a annoncé l'octroi de récompenses d'incitation à six nouveaux employés le 17 janvier 2025. Les récompenses consistent en des options d'achat d'actions non statutaires, permettant d'acquérir jusqu'à 355 000 actions ordinaires de Chimerix. Les options d'achat d'actions ont une durée de 10 ans et seront acquises sur une période de quatre ans, avec 25 % acquises après un an et les 75 % restants acquises mensuellement au cours des trois années suivantes.
Le prix d'exercice est fixé au prix de clôture de Chimerix à la date d'octroi. Bien que soumis aux conditions du Plan d'Incentives en Actions 2024 de Chimerix, ces attributions ont été faites en dehors de celui-ci. L'entreprise, une société biopharmaceutique, développe actuellement dordaviprone (ONC201) pour le gliome H3 K27M mutant et réalise des études d'escalade de doses de Phase 1 pour ONC206.
Chimerix (NASDAQ:CMRX) hat die Gewährung von Anreizvergütungen an sechs neue Mitarbeiter am 17. Januar 2025 bekannt gegeben. Die Vergütungen bestehen aus nichtstatutory Aktienoptionen zum Erwerb von bis zu 355.000 Stammaktien von Chimerix. Die Aktienoptionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre hinweg fällig, wobei 25% nach einem Jahr und die verbleibenden 75% monatlich über die folgenden drei Jahre fällig werden.
Der Ausübungspreis wird zum Schlusskurs von Chimerix am Tag der Gewährung festgelegt. Obwohl sie den Bedingungen des Eigenkapitalanreizplans 2024 von Chimerix unterliegen, wurden diese Zuwendungen außerhalb dieses Plans gewährt. Das Unternehmen, ein biopharmazeutisches Unternehmen, entwickelt derzeit dordaviprone (ONC201) für H3 K27M-mutierenden Gliom und führt Phase-1-Dosissteigerungsstudien für ONC206 durch.
- None.
- None.
DURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on January 17, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to six new employees of non-statutory stock options to purchase up to a total of 355,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4).
The stock options have an exercise price per share equal to Chimerix’s closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the date of hire and the remaining three-fourths vesting over the following three years in equal monthly installments. The stock options are subject to the terms of Chimerix’s 2024 Equity Incentive Plan but were granted outside of the 2024 Equity Incentive Plan.
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
CONTACTS:
Will O’Connor
Stern Investor Relations
212-362-1200
ir@chimerix.com
will@sternir.com
FAQ
How many shares were included in Chimerix's (CMRX) January 2025 inducement stock option grants?
What is the vesting schedule for CMRX's January 2025 inducement stock options?
What is Chimerix's (CMRX) main clinical development program as of January 2025?
What is the term length of CMRX's January 2025 inducement stock options?
